Covered recipient · General Payments record
PETER DEHNEL
Allopathic & Osteopathic Physicians Pediatrics
General Payments · PY2018–2024
$77,169.22
- Reported across 93 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $12,005.70 | 8 |
| Travel and Lodging | $1,133.06 | 2 |
| Food and Beverage | $95.35 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $4,788.00 | 3 |
| LEO Pharma Inc. | $3,948.61 | 6 |
| Incyte Corporation | $2,497.50 | 1 |
| GlaxoSmithKline, LLC. | $2,000.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (11)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $2,000.00 | 05/31/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1116391030 | CMS |
| Incyte Corporation | $2,497.50 | 06/06/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141217052 | CMS |
| LEO Pharma Inc. | $836.98 | 05/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1152625791 | CMS |
| LEO Pharma Inc. | $296.08 | 05/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1152625793 | CMS |
| LEO Pharma Inc. | $95.35 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152625795 | CMS |
| LEO Pharma Inc. | $50.29 | 07/30/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1152625797 | CMS |
| LEO Pharma Inc. | $172.41 | 07/30/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1152625799 | CMS |
| LEO Pharma Inc. | $2,497.50 | 07/30/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1152625801 | CMS |
| Regeneron Pharmaceuticals, Inc. | $684.00 | 01/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1114398083 | CMS |
| Regeneron Pharmaceuticals, Inc. | $2,052.00 | 01/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1114398085 | CMS |
| Regeneron Pharmaceuticals, Inc. | $2,052.00 | 01/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1114398087 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.